open access

Vol 49, No 3 (2017)
Original and clinical articles
Published online: 2017-07-05
Submitted: 2016-12-28
Accepted: 2017-04-14
Get Citation

Do bacteria isolated from ICU patients ‘ESKAPE’ antibiotic treatment? In vitro susceptibility of the Enterobacteriaceae family to tigecycline

Katarzyna Talaga-Ćwiertnia, Paweł Krzyściak, Małgorzata Bulanda
DOI: 10.5603/AIT.a2017.0034
·
Anaesthesiol Intensive Ther 2017;49(3):210-214.

open access

Vol 49, No 3 (2017)
Original and clinical articles
Published online: 2017-07-05
Submitted: 2016-12-28
Accepted: 2017-04-14

Abstract

Background: Enterobacteriaceae are currently causing the majority of healthcare-associated infections (HAI) and
simultaneously expressing increasing levels of antibiotic resistance. The purpose of this study is to assess the in vitro
sensitivity of MDR strains from the family Enterobacteriaceae to tigecycline in relation to their origin from patients
hospitalized in intensive care units (ICUs) and non-ICUs.

Methods: The study involved 156 clinically significant strains of the Enterobacteriaceae family isolated from patients
with complicated intraabdominal infections (cIAIs) and/or complicated skin and skin structure infections (cSSSIs)
hospitalized in ICUs and other surgical departments. Tigecycline MICs were determined by Etest.

Results: The highest percentage of tigecycline non-susceptible (intermediate + resistant strains) in vitro strains
among the Enterobacteriaceae species were observed for Serratia spp. 77.3%, followed by Citrobacter spp. (76.9%)
and Enterobacter spp. (70%); whereas K. pneumoniae and E. coli showed 73–73.8% tigecycline susceptibility rates.

Conclusion: Tigecycline demonstrates a high level of antimicrobial in vitro activity when tested against E. coli and
K. pneumoniae, even those with the ESBL-phenotype. Tigecycline retained activity against merely 22–30% of Enterobacter, Citrobacter and Serratia genera.

Abstract

Background: Enterobacteriaceae are currently causing the majority of healthcare-associated infections (HAI) and
simultaneously expressing increasing levels of antibiotic resistance. The purpose of this study is to assess the in vitro
sensitivity of MDR strains from the family Enterobacteriaceae to tigecycline in relation to their origin from patients
hospitalized in intensive care units (ICUs) and non-ICUs.

Methods: The study involved 156 clinically significant strains of the Enterobacteriaceae family isolated from patients
with complicated intraabdominal infections (cIAIs) and/or complicated skin and skin structure infections (cSSSIs)
hospitalized in ICUs and other surgical departments. Tigecycline MICs were determined by Etest.

Results: The highest percentage of tigecycline non-susceptible (intermediate + resistant strains) in vitro strains
among the Enterobacteriaceae species were observed for Serratia spp. 77.3%, followed by Citrobacter spp. (76.9%)
and Enterobacter spp. (70%); whereas K. pneumoniae and E. coli showed 73–73.8% tigecycline susceptibility rates.

Conclusion: Tigecycline demonstrates a high level of antimicrobial in vitro activity when tested against E. coli and
K. pneumoniae, even those with the ESBL-phenotype. Tigecycline retained activity against merely 22–30% of Enterobacter, Citrobacter and Serratia genera.

Get Citation

Keywords

intensive care unit; Enterobacteriaceae, infections; ESBL; AmpC; MBL; in vitro activity

About this article
Title

Do bacteria isolated from ICU patients ‘ESKAPE’ antibiotic treatment? In vitro susceptibility of the Enterobacteriaceae family to tigecycline

Journal

Anaesthesiology Intensive Therapy

Issue

Vol 49, No 3 (2017)

Pages

210-214

Published online

2017-07-05

DOI

10.5603/AIT.a2017.0034

Bibliographic record

Anaesthesiol Intensive Ther 2017;49(3):210-214.

Keywords

intensive care unit
Enterobacteriaceae
infections
ESBL
AmpC
MBL
in vitro activity

Authors

Katarzyna Talaga-Ćwiertnia
Paweł Krzyściak
Małgorzata Bulanda

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, Świętokrzyska 73 St., 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl